Seer (SEER – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yuko Oku from Morgan Stanley maintained a Hold rating on the stock and has a $3.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yuko Oku has given his Hold rating due to a combination of factors impacting Seer’s financial outlook. The company’s fourth-quarter performance was solid, with revenue aligning with expectations, primarily driven by consumables and services. However, there was a noticeable decline in instrument sales, which affected overall product revenue. This decline is attributed to pressures on capital expenditure budgets and extended sales cycles for new instruments.
Despite the growth in service revenue, uncertainties in U.S. government research funding pose a significant challenge for Seer’s visibility in 2025. With a substantial portion of the company’s revenue coming from academic and government markets, this uncertainty could impact future performance. Additionally, while the company is focusing on strategic studies to drive future growth, these initiatives may not immediately translate into higher revenues. As a result, Yuko Oku maintains a cautious stance with a Hold rating, reflecting both the potential and the risks associated with Seer’s current market position.
SEER’s price has also changed moderately for the past six months – from $1.690 to $1.970, which is a 16.57% increase.